Section Review—Central & Peripheral Nervous Systems: The Evolution of Selective 5-HT_ID Receptor Antagonists

References

• JULIUS D: Molecular biology of serotonin receptors.
   Google Scholar
• •Ann. Rev. Neurosci. (1991) 14:335–360.
   Google Scholar
• HARTIG PR, KAO H-T, MACCHI M, ADHAM N, ZGOMBICK
   Google Scholar
• J, WEINSHANK R, BRANCHEK T: The molecular biology of serotonin receptors; an overview. Neuropsychophar-macol. (1990) 3:335–347.
   Google Scholar
• FRAZIER A, MAAYANI S, WOOLFE BB: Subtypes of receptors for serotonin. Ann. Rev. Pharmacol Toxicol. (1990) 30:307–348. PEROUTKA SJ: 5-HydroxytryptamIrte receptor subtypes: molecular biochemical and physiological charac-terisation. Trends Neurosci. (1988) 11:496–500.
   Google Scholar
• MATTHES H, BOSCHERT U, AMLAIKY N, GRALLHE R, PLASSAT JL, MUSCATELLI F, MATTEI MG, HEN R: The mouse 5-HT5A and 5-HT5u receptors define a new family of serotonin receptors: cloning, functional expression and chromosomal localisation. Mol. Pharmacol (1993) 43:313–319.
   Google Scholar
• MONSMA FJ, SHEN Y, WARD RP, HAMBLIN MW, SIBLEYDR: Cloning and expression of a novel serotonin recep-tor with high affinity for tricyclic psychotropic drugs. Mol. Pharmacol. (1993) 43:320–327.
   PubMed Web of Science ®Google Scholar
• SHEN Y, MONSMA FJ, METCALF MA, JOSE PA, HAMBLINMW, SIBLEY DR: Molecular cloning and expression of a •
   Google Scholar
• -hydroxytryptamine, serotonin receptor subtype. J. Biol. Chem. (1993) 268:18200–18204.
   PubMed Web of Science ®Google Scholar
• HUMPHREY PPA, HARTIG P, HOYER D: A proposed new nomenclature for 5-HT receptors. Trends Ph armacol Sci.(1993) 14:233–236.
   Google Scholar
• HUMPHREY PPA, RICHARDSON BP: Classification of 5-HTreceptors and binding sites: an overview. In: Serotonin, Actions, Receptors, Pathophysiology. Mylecharane JA, de la Lande AIS, Humphrey PPA (Eds.). Macmillan Press, Basing-stoke, UK (1989):204–211.
   Google Scholar
• SCHMIDT AW, PEROUTKA SJ: 5-Hydroxytryptamine re-ceptor 'families' EASES J (1989) 3:2242–2249.
   Google Scholar
• PEROUTKA SJ: 5-Hydroxytryptamine receptor subtypes.
   Google Scholar
• Pharmacology and Toxicology (1990) 67:373–383.
   Google Scholar
• HOYER D, CLARKE DE, FOZARD JR, HARTIG PR, MARTIN ••GR, MYLECHARANE EJ, SAXENA PR, HUMPHREY PPA: VII.International Union of Pharmacology. Classification of receptors for 5-hydroycytryptamine (Serotonin). Phar-macological Reviews (1994) 46(2):157–203.
   Google Scholar
• ZGOMBIC JM, SCHECHTER LE, MACCHI M, HARTIG PR, BRANCHEK TA, WEINSHANK RL: Human gene S31 en-codes the pharmacologically defined serotonin 5-hy-droxytryptamineiz receptor. Mot. Pharmacol. (1992) 42:180–185.
   Google Scholar
• GUDERMAN T, LEVY FO, BIRNBAUMER M, BIRNBAUMER L, KAUMAN AJ: Human S31 serotonin receptor clone encodes a 5-hydroxytryptamineiz-like serotonin recep-tor. Mol. Pharmacol. (1993) 43:412–418.
   PubMed Web of Science ®Google Scholar
• ADHAM N, KAE H-T, SCHECHTER LE, BARD J, OLSEN M,URQUHART D, DURKIN M, HARTIG PR, WEINSHANK RL, • BRANCHEK TA: Cloning of another human serotonin receptor (5-HT1F): A fifth 5-HT1 receptor subtype cou-pled to the inhibition of adenylate cyclase. Proc. Natl. Acad. Sci. (1993) 90:408–412.
   PubMed Web of Science ®Google Scholar
• DOURISH CT: 5-H1'1A receptors and anxiety. In: Brain5-H7'1A Receptors; Behavioural and Neurochemical Pharnza-cology. Alhenius S, Hutson PH (Eds.). Ellis Horwood Ltd., Chichester, UK (1987):261–278.
   Google Scholar
• CLIFFE IA, FLETCHER A, DOURISH CT: The evolution ofselective, silent 5-HTiA receptor antagonists. Current Drugs (1993), 99–123.
   Google Scholar
• GLENNON RA, DUKAT M: 5-11T receptor ligancls - update
   Google Scholar
• Current Drugs (1992):1–45.
   Google Scholar
• •
   Google Scholar
• ROUTLEDGE C: The development of selective 5-HT receptor antagonists. Behav. Brain Res. (1995). In press.
   Google Scholar
• CHARLTON KG, BOND RA, CLARK DE: An inhibitory prejunctional 5-H11-like receptor in the isolated per-fused rat kidney. Apparent distinction from the 5-HT1A, 5-HT15 and 5-HT5c subtypes. Naunyn-Schmiedeberg's Arch. Pharmacol. (1986) 332:8–25.
   Google Scholar
• GOTHERT M, SCHLICKER E, KOLLECKER P: Receptor-me-diated effects of serotonin and 5-methoxytryptamine on noradrenaline release in the rat vena cava and in the heart of the pithed rat. Naunyn-Schmiedeberg's Arch. Pharmacol. (1986) 332:124–130.
   Google Scholar
• MOLDERINGS GL, FINK K, SCHLICKER E, GOTHERT M: •Inhibition of noradrenallne release via presynaptic 5-HTis receptors of the rat vena cava. Naunyn-Schmiede-berg's Arch. Pharmacol. (1987) 336:245–250.
   Google Scholar
• ENGEL G, GOTHERT M, HOYER D, SCHLICKER E, • BRAND K: Identity of inhibitory presynaptic 5-hy-droxytryptarnine (5-HT) autoreceptors in the rat brain cortex with 5-HT1B binding sites. Naunyn-Schmiedeberg's Arch. Pharmacol. (1986) 332:1–7.
   Google Scholar
• GOTHERT M, SCHLICKER E, FINK K, CLASSEN K: Effects of •RU 24969 on serotonin release in rat brain cortex Further support for the identity of serotonin autorecep-tors with 5-HTin sites. Arch. Int. Pharmacodyn. (1987) 288:31–42.
   Google Scholar
• RAITERI M, MAURA G, BONNANO G, PITTALUGA A: Dif-ferential pharmacology and function of two 5-HT1 re-ceptors modulating transmitter release in the rat cerebellum. J. Pharmacol. Exp. Tber. (1986) 237:644–648.
   PubMed Web of Science ®Google Scholar
• MIDDLEMISS DN: 8-Hydroxy-2-(di-n-propylamino) tetralin is devoid of activity at the 5-hydroxytryptamine autoreceptor in rat brain. Implications for the pro-posed link between the autoreceptor and the [311J 5-HT recognition site. Naunyn-Schmiedeberg's Arch . Pharmacol. (1984) 327:18–22.
   Google Scholar
• MIDDLEMISS DN: The putative 5-H1i receptor agonist,RU 24969, inhibits the efflux of 5-hydroxytryptamine from rat frontal cortex slices by stimulation of the 5-LIT autoreceptor. J.Pharm. Pharmacol. (1985) 37:434–438.
   PubMed Web of Science ®Google Scholar
• MIDDLEMISS DN: Blockade of the central 5-11T autore-ceptor by P-adrenoceptor antagonists. Earl. Pharmacol. (1986) 120:51–54.
   PubMed Web of Science ®Google Scholar
• GLENNON RA: Serotonin receptors and site selective agents. J. Physiol. Pharmacol. (1991) 1:49–60.
   Google Scholar
• SCHOEFFTER P, HOYER D: Interaction of arylpiperazi- nes with 5-FIT1A,5-HTic and 5-HTin receptors.Do discriminatory 5-HTH) ligands exist? Naunyn-
   Google Scholar
• Schmiedeberg's Arch. Pharmacol. (1989) 339:675–683.
   Google Scholar
• MACOR JE, BURKHART CA, HEYM JH, IVES JL, LEBEL LA, NEWMAN ME, NIELSEN A, RYAN K, SCHULZ DW, TOR-GERSEN LK, KOE BK: 341,2,5,6-tetrahydropyrid-4-yl)pyrrolo[3,2-1/1pyrid-5-one: A potent and selective serotonin (5-HTis) agonist and rotationally restricted analogues of 5-methoxy-341,2,5,6-tetrahydropyrid-4-yOindole. J. Med. Chem. (1990) 33:2087–2093.
   PubMed Web of Science ®Google Scholar
• HEURING RE, PEROUTKA SJ: Characterisation of a novel [311]-5-hydroxytryptamine binding subtype in bovine brain membranes. J. Neurosci. (1987) 7(3):894–903.
   PubMed Web of Science ®Google Scholar
• WAEBER C, SCHOEFTER P, HOYER D, PALACIOS JM: The serotonin 5-HTio receptor: a progress review. Neuro-chem. Res. (1990) 15:567–582.
   Google Scholar
• WAEBER C, SCHOEFHER P, PALACIOS JM, HOYER D: •Molecular pharmacology of 5-HTin recognition sites: Radioligand binding studies in human, pig and calf brain membranes. Naunyn-Schmiedeberg's Arch. Pharma-col. (1988) 337:595–601.
   Google Scholar
• HAMEL E, FAN E, LINWIJ F D, TING V, VILLEMURE JG, CHIA• LS: Expression of mRNA for the serotonin 5-hy-droxytryptaminenv receptor subtype in human and bovine cerebral arteries. Mol. Pharmacol. (1993) 44:242–246.
   PubMed Web of Science ®Google Scholar
• HAMEL E, GREGOIRE L, LAU B: 5-HT1 receptors mediating contraction in bovine cerebral arteries: a model for human cerebrovascular `5-HTipp' receptors. Eur.J. Phar-macol. (1993) 242:75–82.
   Google Scholar
• HUMPHREY PPA, FENUIK W, PERREN MJ, CONNOR HE, OXFORD AW, COATES IH, BUTINA D: GR43175, a selec-tive agonist for the 5-HT1-like receptor in dog isolated saphenous vein. Br. J. Pharmacol. (1988) 94:1123–1132.
   PubMed Web of Science ®Google Scholar
• WAEBER C, PALACIOS JM: 5-HT receptor binding sites in the guinea pig superior colliculus are predominantly of the 5-HTin class and are presynaptically located on primary retinal afferents. Brain Res. (1990) 528:207–218.
   PubMed Web of Science ®Google Scholar
• GONZALEZ-HEYDRICH J, PEROUTKA SJ: Postsynaptic lo-calisation of 5-HTw receptor binding sites in human caudate. Exp. Neurol. (1991) 113:28–30.
   PubMed Web of Science ®Google Scholar
• HOYER D, MIDDLEMISS DN: Species differences in the pharmacology of terminal 5-11T autoreceptors in mam-malian brain. Trends. Pharmacol. Sci. (1989) 10:130–132.
   PubMed Web of Science ®Google Scholar
• MAURA G, THELLUNG S, ANDREOLI GC, RUELLE A, RAIT- ••ERI M: Release-regulating 5-HTin serotonin autoreceptors in human cerebral cortex. J. Neurochern. (1993) 60:1179–1182.
   Google Scholar
• HAMBLIN MW, METCALF MA: Primary structure and functional characterisation of a human 5-HTio-type serotonin receptor. Mol. Pharmacol. (1991) 40:143–148.
   Google Scholar
• HARTIG PR, BRANCHEK TA, WEINSHANK RL: A subfamily of 5-HTin receptor genes. Trends. Pharmacol. Sci. (1992) 13:152–159.
   Google Scholar
• WEINSHANK RL, ZGOMBIC JM, MACCHI MJ, BRANCHEK TA, HARTIG PR: Human serotonin 1D receptor is en-coded by a subfamily of two distinct genes: 5-HTma and 5-HT1pp. Proc. Nat. Acad. Sci. (1992) 89:3630–3634.
   PubMed Web of Science ®Google Scholar
• METCALF MA, MCGUFFIN RW, HAMBLIN MW: Conversion of the human 5-HTio beta ligand binding serotonin tothe 5-HT1s ligand-binding phenotype by Thr355/Asn351 site directed mutagenesis. Biochem. Pharmacol (1992) 44(10):1917–1920.
   Google Scholar
• PARKER EM, GRISEL DA, IBEN LG, SHAPIRO RA: A single amino add difference accounts for the pharmacologi-cal distinctions between the rat and human 5-hy-droxytryptaminen receptors. J. Neurochem. (1993) 60(1):380–383.
   Google Scholar
• BRANCHEK TA: Site-directed mutagenesis of serotonin receptors. Med. Chem. Res. (1993) 3:287–296.
   Google Scholar
• HOENICKE A, BRAND J, PERRIN VL: Possible benefit of GR43175, a novel 5-HTt-like receptor agonist, for the acute treatment of migraine. Lancet (1988) i:1309–1311.
   Google Scholar
• SCHOEWIER P, HOYER D: How selective is GR43175? Interactions with functional 5-HT1A, 5-11Tts, 5-HTic and 5-HT1D binding sites. Naunyn-Schmiedeberg's Arch. Phar-macol. (1989) 340:135–138.
   PubMed Web of Science ®Google Scholar
• PEROUTKA SJ, MCCARTHY BG: Sumatriptan (GR43175) interacts selectively with 5-HT m and 5-HT'', binding sites. Eur. J. Pharmacol (1989) 163:133–136.
   PubMed Web of Science ®Google Scholar
• BEER MS, STANTON JA, BEVAN Y, HEALD A, REEVE AJ, STREET LJ, MATASSA VG, HARGREAVES RJ, MIDDLEMISS DN: L-694,247: a potent 5-HTto receptor agonist. Brit.J. Pharmacol. (1993) 110:1196–1200.
   PubMed Web of Science ®Google Scholar
• BRUINVELS AT, LANDWEHRMEYER B, WAEBER C, PALACIOS JM, HOVER D: Homogeneous 5-HTto recogni-tion sites in the human substantia nigra identified with a new iodinated radioligand. Eur. J. Pharmacol. (1991) 202:89-91. GLENNON RA, WESTKAEMPER RB: 5-HT10 receptors: A serotonin receptor for the 19905. Drug News & Perspec-tives (1993) 6:390-405. GLENNON RA, DUKAT M: Serotonin receptors and their ligands: a lack of selective agents. Pharmacol. Biochem. Behav. (1991) 40:1009–1017.
   Google Scholar
• RISCH SC, NEMEROFF CB: Neurochemical alterations of serotonergic neuronal systems in depression. J. Clin. Psychiatry (1992) 53(Suppl.):3–7.
   Google Scholar
• DELGADO PL, CHARNEY DS, PRICE LH, AGHAJANIAN GK, LANDIS H, HENINGER GR: Serotonin function and the mechanism of antidepressant action: reversal of anti-depressant-induced remission by rapid depletion of plasma lryptophan. Arch. Gen. Psychiatr. (.990) 47:411–419.
   Google Scholar
• HOLLIDAY SM, PLOSKER GL: Paroxetine. A review of itspharmacology, therapeutic use in depression and therapeutic potential in diabetic neuropathy. Drugs Aging (1993) 3(3):278–299.
   Google Scholar
• ZEMLAN FP, GARVER DL: Depression and antidepressant therapy: receptor dynamics. Prog. Neuropsychopharma-col. Biol. Psychiatry (1990) 14(4):503–523.
   Google Scholar
• BRILEY M, MORET C: 5-HTin autoreceptor antagonists aspotential antidepressants. 5-HT and antidepressants: in vitro and in vivo release studies. Trends Pharmacol. Sci. (1993) 14:396–397.
   Google Scholar
• SCOPES DIC, CLITHEROW JW, MITCHELL WL, KELLY HA, IRVING W, CAMPBELL IB, OXFORD AW, COLLINGTON EW, JORDAN CC, SKINGLE M, FENIUK W, CONNOR H, TYERS MB: Selective 5-HTin antagonists: a novel series of biaryl anilides. 207th National Meeting of the American Chemical Society, San Diego, March 13–17 (1994):MEDI 164,
   Google Scholar
• SCOPES DIG, CLITHEROW JW, CARTER MC, IRVING W, COLLINGTON EW, SKINGLE M, FENIUK W, TYERS MB: Heterocyclic biarylanilides as potent 5-11Tm antago-nists. Ibid.:MEDI 165.
   Google Scholar
• CLITHEROW JW, SCOPES DIG, SKINGLE M, JORDAN CC, FENIUK W, CAMPBELL IB, CARTER MC, COLLINGTON EW, CONNOR HE, HIGGINS GA, BEATTIE D, KELLY HA, MITCHELL WL, OXFORD AW, WADSWORTH AH, TYERS MB: Evolution of a novel series of (N,N-dimethy-lamino)propyl- and piperazinobenzanilides as the first selective 5-HT) D antagonists. J. Med. Chem. (1994) 37(15):2253–2257.
   Google Scholar
• SKINGLE M, HIGGINS GA, FENIUK W: Stimulation of central 5-HT1D receptors causes hypothermia in theguinea-pig. J Psychopharmacol. (1994) 8:14–21.
   Google Scholar
• HIGGINS GA, JORDAN CC, SKINGLE M: Evidence that unilateral activation of 5-HTio receptors in the substan-tia nigra of the guinea-pig elicits contralateral rotation. Br. J. Pharmacol. (1991) 102:305–310.
   PubMed Web of Science ®Google Scholar
• SKINGLE M, BEATTIE DT, SCOPES DIG, STARKEY SJ, CON-NOR HE, FENIUK W, HUMPHREY PPA, TYERS MB: GR127935: a potent and selective 5-HTt0 receptor an-tagonist. Behav. Brain Res. (1995). In press.
   Google Scholar
• SKINGLE M, SLEIGHT AJ, FENIUK W: Effects of the 5-HT receptor antagonist GR 127935 on extracellular levels of5-HT in the guinea-pig frontal cortex as measured by microdialysis. Neuropharrnacol. (1995). In press.
   Google Scholar
• CRESPI F, GARRATT JC, SLEIGHT AJ, MARSDEN CA: In vivo evidence that 5-HT neuronal firing rate and release are not necessarily correlated with 5-HT metabolism. Neurosci. (1990) 35:139–144.
   PubMed Web of Science ®Google Scholar
• SKINGLE M, SLEIGHT AJ, ROSSER DJ: Effect of local Infusions of 8-0H DPAT on extracelhdar levels of 5-HT in the anaesthetised guinea-pig. Soc. Neurosci. Abstr. (1992) 18:46.4.
   Google Scholar
• STARKEY SJ, SKINGLE M: 5-11Tm as well as 5-HT1A autoreceptors modulate 5-HT release in the guinea-pig dorsalraphe nucleus. Neuropharmacol. (1994) 33:393–402.
   Google Scholar
• SPROUSE JS, AGHAJANIAN GK: Electrophysiological re-sponses of serotonergic dorsal raphe neurones to 5-HT1A and 5-HTm agonists. Synapse (1987) 13–9.
   Google Scholar
• SKINGLE M, SCOPES DIG, FENIUK W, TYERS MB, CONNOR HE, CARTER MC, CLITHEROWGR127835: A potentorally active 5-RTm receptor antagonist. Br. J. Pharma-col. (1993) 110:9P.69.
   Google Scholar
• ••
   Google Scholar
• SKINGLE M, COLE N, HIGGINS G, FENIUK W: Inhibitionof DOI-induced wet-dog shakes in the guinea-pig by 5-11T2 receptor antagonists. J. Psychopharmacol. (1991) 5:196–201.
   PubMedGoogle Scholar
• ROBERTS C, THORN L, PRICE GW, MIDDLEMISS DNJONESBJ: Effect of the selective receptor antagonist, GR127935, on in vivo 5-LIT release, synthesis and turn-over in the guinea-pig frontal cortex. Br. J. Pharmacol. (1994) 112:489P.
   Google Scholar
• ADELL A, ARTIGAS F: Differential effects of clomipramine given locally or systemically on extracellular 5-hydroxytryptamine in raphe nuclei and frontal cor-tex. An in vivo brain microdialysis study. Naunyn-Schmiedeberg's Arch. Pharmacol. (1991) 343:237–244.
   Google Scholar
• HOGG JE, HUTSON PH: Effects of fluoxetine, methiothepin and GR127935 on 5-HT efflux in the guinea-pig cortex in vivo. Br. J. Pharmacol. (1994) 112:644P.
   Google Scholar